

Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Microbiology Research

Journal homepage: <https://www.ijmronline.org/>

Review Article

RNAi: antifungal therapy against Invasive pulmonary aspergillosis (IPA) in humans

Maneesh Kumar^{1,*}, Roshan Kamal Topno², Ratnesh Kumar³

¹Dept. of Biotechnology, Magadh University, Bodh Gaya, Bihar, India

²Dept. of Microbiology, Sri Venkateswara Medical College, Tirupati, Andhra Pradesh, India

³Dept. of Microbiology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India



ARTICLE INFO

Article history:

Received 27-06-2023

Accepted 08-08-2023

Available online 10-10-2023

Keywords:

miRNAs

Aspergillus

Aspergillosis

Immune reactions

Antifungal therapy

ABSTRACT

Noncoding RNAs, known as miRNAs, regulate gene expression. Most miRNAs are converted from DNA sequences into primary miRNAs, processed into precursors, and matured. Survival or virulence of *Aspergillus* species is targeted by RNAi antifungal treatment. Silencing these genes can reduce fungal proliferation and pathogenicity, thereby improving therapy. RNAi can be used to treat *Aspergillus*; however, most research has been conducted in controlled laboratory or animal studies. The immune system neutralizes *Aspergillus* spores, so not everyone gets sick. Aspergillosis can range from moderate allergic reactions to invasive, life-threatening disease. MiRNAs have been studied in numerous diseases, but their role in immune responses to pulmonary and systemic fungal infections is still being discovered. During disease progression, fungal pathogens can alter signaling and expression of miRNAs in the genetic network. Future investigations on the biological purpose of miRNAs, previously assumed to be a consequence of miRNA synthesis, will illuminate the regulatory function of the miRNA network in plant innate immunity. MiRNAs and their intended targets present opportunities for novel pathogen-fighting strategies and technologies.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

RNA interference (RNAi) is a biological mechanism that controls gene expression. RNAi controls gene expression, development, and viral defense. While RNAi has been extensively studied and used for gene silencing in various research areas, including antiviral and anticancer therapies, its application as an antifungal therapy against IPA in humans is still in the early stages of exploration.^{1–3} The idea behind using RNAi as an antifungal therapy is to target specific genes or gene products essential for the survival or virulence of *Aspergillus* species.⁴ Silencing these genes has the potential to reduce the proliferation and pathogenicity of the fungi, which could improve the

efficacy of treatment.^{2,5} While RNAi has shown some promise in treating *Aspergillus*, most of the research done on the topic has been conducted in controlled laboratory or animal environments. The core principle of employing RNAi against Aspergillosis is to selective target and silence specific genes or gene products important for the survival or pathogenicity of *Aspergillus* species.⁶ By blocking the expression of these essential genes, it is feasible to impede the growth and pathogenicity of the fungi, potentially boosting the effectiveness of treatment. Several studies have shown favorable evidence for the feasibility of RNAi-based antifungal therapy against IPA.⁷

IPA is a fungal infection caused by *Aspergillus* species, and it poses significant challenges to human health, particularly in individuals with weakened immune systems.

* Corresponding author.

E-mail address: kumar.maneesh11@gmail.com (M. Kumar).

This group of fungi is ubiquitous in the environment and commonly found in soil, decaying organic matter, and indoor environments.^{8,9} While there are many species of *Aspergillus*, the one most frequently associated with human disease is *A. fumigatus*.⁵ Other species, such as *A. flavus*, *A. niger*, and *A. terreus* can also cause infections.^{2,10} Its spores are microscopic and easily dispersed in the air. When inhaled, they can reach the respiratory system and potentially cause infection, particularly in individuals with compromised immune systems or underlying respiratory conditions.¹¹ However, not everyone exposed to *Aspergillus* spores develops an infection, as the immune system is generally able to neutralize them. There are different types of aspergillosis, ranging from mild allergic reactions to invasive and life-threatening infections.¹² Allergic bronchopulmonary aspergillosis (ABPA) is an allergic response in individuals with asthma or cystic fibrosis, resulting in respiratory symptoms. Chronic pulmonary aspergillosis (CPA) primarily affects individuals with underlying lung conditions, causing long-term lung damage. Invasive aspergillosis is the most severe form, occurring mainly in immunocompromised individuals and potentially spreading beyond the lungs to other organs, leading to significant morbidity and mortality.^{13,14} Many researchers are focusing their attention on critical genes that are currently engaged in the formation of fungal cell walls or signaling pathways. Researchers have been able to successfully inhibit the growth of *Aspergillus* in the laboratory as well as in animal models by delivering tiny interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) that selectively target these genes. This has allowed them to diminish the virulence of the fungus.¹⁵ In the review study of IPA, RNA interference (RNAi) has been used as an antifungal drug by targeting genes needed for fungal cell wall formation and signal transmission. In experimental settings, tiny interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) that preferentially target these genes have been shown to inhibit *Aspergillus* growth and decrease pathogenicity.

2. Chemistry of RNAi

RNAi begins with the synthesis of short double-stranded RNA (dsRNA) molecules. They are synthesized by using enzymes known as RNA polymerase II and III that are responsible for microRNA synthesis. In the presence of the microprocessor multi-protein complex and co-factor DiGeorge syndrome Critical Region 8 (DGCR8/Pasha), primary microRNAs (pri-miRNA) is turned into precursor miRNA (pre-miRNA).¹⁶ They are complementary to the target gene's messenger RNA (mRNA). These dsRNA molecules can be created synthetically or produced naturally within cells. The dsRNA is then processed by an enzyme called Dicer, which cleaves it into smaller fragments known as small interfering RNA (siRNA). The siRNA is then

loaded onto a protein complex called the RNA-induced silencing complex (RISC). One strand of the siRNA is kept safe within the RISC, while the other is thrown away. The last strand of siRNA directs the RISC complex to the target mRNA, where it attaches, which either causes the mRNA to be degraded or stops it from being translated into protein (Figure 1). This mechanism allows for accurate gene control and efficiently lowers the expression of the target gene.^{17,18}




Fig. 1: The general role of RNAi

The RNA interference (RNAi) complex plays a critical role in combating fungal infections by targeting and inhibiting the expression of specific fungal genes. When the host organism detects the presence of fungal pathogens, it activates the RNAi pathway as a defense mechanism.⁴ The pathway leads to the production of small interfering RNAs (siRNAs) that can selectively bind to complementary sequences in fungal mRNA. This binding leads to the degradation of the fungal mRNA or inhibits its translation, effectively reducing the expression of essential fungal genes. By disrupting fungal gene expression, RNAi helps to control and mitigate the spread of fungal infections in the host organism.^{19,20} The RNAi complex can act both in the host organism's cells and as an extracellular defense mechanism. Inside the host cells, it prevents the replication and spread of fungal pathogens by silencing their genes. Outside the cells, the RNAi complex can be secreted and released into the extracellular space, where

it can directly target and neutralize fungal elements.²¹ In addition to its direct antifungal effects, the RNAi complex can also stimulate the host immune response. It can activate immune cells and enhance their ability to recognize and eliminate fungal invaders.²² This collaboration between the RNAi complex and the immune system further strengthens the host's defense against fungal infections. Overall, the RNAi complex plays a crucial role in combating fungal infections by selectively targeting and suppressing fungal gene expression.²³ Its ability to disrupt vital fungal genes and stimulate the immune response makes it a promising avenue for the development of novel antifungal therapies.




Fig. 2: RNA interference (RNAi) targets and inhibits fungal genes to fight infections

3. Function of MicroRNAs in Immune Control

The involvement of microRNAs in the regulation of immunological responses, including the formation, development, activation, functioning, and ageing of different types of immune cells, has been the subject of a vast number of publications. It has been discovered that many different miRNAs display extremely specialized expression patterns in organs that are connected with the immune system's function. Even the transformation of progenitor cells of the hematopoietic system down the path of the lymphoid or myeloid lineage can be controlled by the expression profile of distinct microRNA.²⁴ This strongly points to the fact that miRNAs play a substantial role in the development and operation of immune cells. The impact that microRNAs have on the progression of a wide range of diseases is due to the fact that they have an effect on both the innate and adaptive immune responses. Therefore, it is essential to have an understanding of how diverse physiological functions of the body's immune system are

regulated by miRNAs, both in a healthy condition and in a sick state.^{25–27}

4. The miRNAs involved in Inflammation during *Aspergillus* Infection

IPA kills more than 80% of immunocompromised people, including patients with blood cancers and bone marrow transplant recipients. Although the true prevalence of IPA remains unclear, it was once thought that between 30% and 50% of invasive fungal illnesses in immunocompromised people were caused by this condition. Because of the growing body of evidence that miRNAs control host responses to viral, bacterial, and fungal infections, it is likely that they play a role in IPA pathogenesis, which is still little understood.²³ Although miRNAs have been studied in many illnesses, their function in understanding the immune response to pulmonary and systemic fungal exposure is still developing. Fungal pathogens may affect miRNA genetic network signaling and shift expression profiles during disease progression.^{28,29} MicroRNAs regulate most biological activities endogenously. Freely circulating miRNAs may be biomarkers for extrapulmonary illnesses, according to recent studies. Hypoxia-related miRNAs, such as miRNA-26a, miRNA-26b, miRNA-21, and miRNA-101, were considered when lung hypoxia became apparent due to an ischemic microenvironment, vascular invasion, thrombosis, and antiangiogenic factors like gliotoxin.^{30,31} A study examined miRNA-132 and miRNA-155 expression among human monocytes and dendritic cells following *A. fumigatus* infection. *A. fumigatus*, or bacterial lipopolysaccharide induction, differently expressed miRNA-132 and miRNA-155 in monocytes and DCs. Surprisingly; *A. fumigatus* activated miRNA-132 in monocytes and DCs, whereas LPS did not. This suggests that miRNA-132 may regulate the immune response against *A. fumigatus*.³²

The most common causes of aspergillosis are the fungi *A. fumigatus* and *A. flavus*. Clinical observations and serological tests form the backbone of the diagnostic process. After a lung biopsy or bronchoalveolar lavage (BAL), histological testing and tissue culture are the gold standards. However, in severe cases like thrombocytopenia, this intrusive method is not recommended. Due to the lack of an immediately available standard diagnostic test, the high mortality rate associated with IPA poses a significant problem.^{33–35}

Chen and his team initially worked on the inflammation due to IPA. They injected cyclophosphamide intraperitoneally into mice to create a neutropenic model and found that the mice's neutrophil count remained below 100/mm³ throughout the study. *A. fumigatus* was able to infect mice with weakened immune systems. On day four after the infection, the mice stopped eating, stopped moving around, and eventually stopped breathing. On day one post-inoculation, infected lung tissues had

the highest fungal burden, which decreased with time. Gross pathologic alterations included a rise in bleeding as well as the development of white nodular lesions. A group of hyphae was seen under the microscope when *A. fumigatus* spores germinated in lung tissue.³⁶ These findings demonstrated the validity of the IPA mouse model. For this they used NGS to perform a global miRNA profile in the lung tissues of mice that had either been exposed to IPA or served as controls. Our goal was to determine which and how many miRNAs are likely implicated in the pathogenesis of IPA.³⁷

The genus *Aspergillus* contains numerous species of filamentous fungi that are widely distributed around the globe and can be found in a wide variety of habitats. The most common member of this genus, *A. fumigatus*, is largely responsible for the rise in the incidence of invasive aspergillosis, which carries a significant fatality rate in immunocompromised patients.^{38,39} *A. fumigatus* is currently the leading cause of death in leukaemia patients and is responsible for a high number of nosocomial opportunistic fungal infections in immunocompromised hosts, especially during cytotoxic chemotherapy and following bone marrow transplantation.⁴⁰ Conidia (resting spores) of *Aspergillus* are found everywhere, are frequently breathed, and are rapidly phagocytized by the alveolar macrophages and neutrophils of an immunocompetent host. However, if immunocompromised people are unable to effectively germinate conidia, they may get invasive pneumonia and systemic infections.³¹ It has been used as a model to investigate the function of the cell wall in the evolution and pathogenesis of filamentous fungi because of its clinical importance.

Following an infection, there are discernible shifts in the profiles of the circulating microRNAs. It has been demonstrated that an infection with *Candida albicans* causes an increase in the production of several microRNAs, including miR-455, miR-125a, miR-146, and miR-155, in the macrophages of rats.⁴¹ In rats with candidemia-induced kidney damage, the expression of miR-204 and miR-211 was found to be reduced in kidney tissue.⁴² Both miR-132 and miR-155 revealed increased levels of expression in monocytes and dendritic cells that had been infected with *A. fumigatus*.^{31,41} The patients who were infected with *P. brasiliensis* had elevated expression of 8 microRNAs that were connected to apoptosis and immunological response, according to the serum study. The information in Table 1 illustrates how IPA may cause certain essential miRNA to become potentially active.

5. Perspectives of miRNAs during IPA

MiRNAs have been found to play a role in the development and progression of invasive pulmonary aspergillosis (IPA), an opportunistic infection caused by the fungal pathogens like *A. fumigatus*, *A. flavus* and

Table 1: List of miRNA involved in Invasive pulmonary aspergillosis

miRNA	Involvement in Invasive pulmonary aspergillosis	Reference
miRNA-155	Regulates immune response and inflammation during <i>Aspergillus</i> infection	24,32
miRNA-132	Plays a role in the host defense against <i>A. fumigatus</i> infection	32
miRNA-17-5p	Implicated in the regulation of fungal growth and host immune response	43
miRNA-155-5p	Regulates inflammatory response and cytokine production during infection	44
miRNA-23b	Modulates the host immune response to <i>A. fumigatus</i> infection	45
miRNA-21	Involved in the regulation of apoptosis and inflammation during infection	24
miRNA-31	Regulates the expression of host defense genes and cytokine production during <i>Aspergillus</i> infection	46
miRNA-146a	Regulates Toll-like receptor signaling pathway and inflammation	47
miRNA-132-3p	Implicated in the modulation of cytokine production and immune response	46
miRNA-9	Plays a role in the regulation of antifungal immune responses	48
miR-17-92 cluster	Regulates immune responses and antifungal defense mechanisms during fungal infections, including <i>Aspergillus</i> .	49

many more. MiRNAs regulate gene expression in response to environmental signals, and studies have shown that miRNA expression profiles differ in IPA patients compared to healthy individuals. These differentially expressed miRNAs have been found to modulate the immune response to fungal infection in various ways, including by promoting apoptosis, decreasing antibody production, and decreasing the production of pro-inflammatory cytokines.⁵⁰ Additionally, miRNAs have been identified that promote the proliferation and differentiation of pulmonary cells, suggesting a potential for miRNA therapy in IPA. As research on miRNAs and IPA continues to develop, patient management protocols may be altered to provide therapies targeting the disease-associated miRNAs. Recent studies have focused on this phenomenon in fungi and its involvement in fungal infections. In particular, miRNAs can modulate the expression level of target genes involved in the initiation, perpetuation, and/or maintenance of fungal infections. This includes regulation of pathogenicity, adherence, infectivity, and evasion from the host immune system.

6. Conclusion

The significance of microRNAs (miRNAs) in the arms race between hosts and pathogens is a topic that needs greater attention in the future. It is not well known, for instance, how fungal infections secrete and transmit short RNA effectors to the plant host or how the plant exports sRNAs to induce cross-kingdom gene silencing. The regulatory role of miRNA networks in plant innate immunity will be better understood as a result of future studies into the biological function of miRNAs, which were previously thought to be a byproduct of miRNA synthesis. Opportunities for the development of novel tactics and technology to enhance human resistance to pathogens are also presented by miRNAs and their targets.

7. Source of Funding

None.

8. Conflict of Interest

None.

References

- Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. *Gene*. 2014;538(2):217–27.
- Gilbert MK, Majumdar R, Rajasekaran K, Chen ZY, Wei Q, Sickler CM, et al. RNA interference-based silencing of the alpha-amylase (amy1) gene in *Aspergillus flavus* decreases fungal growth and aflatoxin production in maize kernels. *Planta*. 2018;247:1465–73.
- Chakravarty M, Vora A, Drug Deliv Transl Res. Nanotechnology-based antiviral therapeutics. 2021;11(3):748–87.
- Majumdar R, Rajasekaran K, Cary JW. RNA interference (RNAi) as a potential tool for control of mycotoxin contamination in crop plants: concepts and considerations. *Front Plant Sci*. 2017;8:200.
- Kelani AA, Bruch A, Rivieccio F, Visser C, Krueger T, Weaver D, et al. Disruption of the *Aspergillus fumigatus* RNA interference machinery alters the conidial transcriptome. *RNA*. 2023;29(7):1033–50.
- Lax C, Tahiri G, Patiño-Medina JA, Cánovas-Márquez JT, Pérez-Ruiz JA, Osorio-Concepción M, et al. The evolutionary significance of RNAi in the fungal kingdom. *Int J Mol Sci*. 2020;21(24):9348. doi:10.3390/ijms21249348.
- Trieu TA, Navarro-Mendoza MI, Pérez-Arques C, Sanchis M, Capilla J, Navarro-Rodríguez P, et al. RNAi-based functional genomics identifies new virulence determinants in mucormycosis. *PLoS Pathog*. 2017;13(1):e1006150. doi:10.1371/journal.ppat.1006150.
- Paulussen C, Hallsworth JE, Álvarez Pérez S, Nierman WC, Hamill PG, Blain D. Ecology of aspergillosis: insights into the pathogenic potency of *Aspergillus fumigatus* and some other *Aspergillus* species. *Microb Biotechnol*. 2017;10(2):296–322.
- Bajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park YH. Invasive fungal infections and their epidemiology: Measures in the clinical scenario. *Biotechnol Bioprocess Eng*. 2019;24:436–44.
- Kelani AA, Bruch A, Rivieccio F, Visser C, Krueger T, Weaver D, et al. Disruption of the *Aspergillus fumigatus* RNA interference machinery alters the conidial transcriptome. *RNA*. 2023;29(7):1033–50.
- Sabino R, Verissimo C, Viegas C, Viegas S, Brandão J, Alves-Correia M, et al. The role of occupational *Aspergillus* exposure in the development of diseases. *Med Mycol*. 2019;57(Supplement_2):196–205.
- Baruah C, Devi P, Deka B, Sharma DK. Mucormycosis and Aspergillosis have been linked to Covid-19-related fungal infections in India. *Adv Case Stud*. 2021;3:1–4.
- Keown K, Abbott S, Kuzeljevic B, Rayment JH, Chilvers MA, Yang CL. An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis. *Pediatr Pulmonol*. 2019;54(11):1787–93.
- Sunman B, Tural DA, Ozsezen B, Emiralioğlu N, Yalcin E, Özçelik U. Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis. *Front Pediatr*. 2020;8:582964. doi:10.3389/fped.2020.582964.
- Kumar M. In silico efficacy of [S]-8-gingerol (a derivative) with 6-gingerol against PT-domain of Polyketide synthase A (PksA). *IP Int J Med Microbiol Trop Dis*. 2021;7(1):62–4.
- Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. *Nat Rev Mol Cell Biol*. 2019;20(1):5–20.
- Tanui P, Kennedy SD, Lunstad BD, Haas A, Leake D, Rozners E. Synthesis, biophysical studies and RNA interference activity of RNA having three consecutive amide linkages. *Org Biomol Chem*. 2014;12(8):1207–10.
- Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise. *Annu Rev Pharmacol Toxicol*. 2016;56:103–22.
- Kumar P, Kumar M, Kumar H, Kumar J. In vitro effects of rosuvastatin on *Mycobacterium tuberculosis*. *Int J Curr Res Life Sci*. 2018;7(4):1885–7.
- Cai Q, He B, Weiberg A, Buck AH, Jin H. Small RNAs and extracellular vesicles: New mechanisms of cross-species communication and innovative tools for disease control. *PLoS Pathog*. 2019;15(12):e1008090.
- Wang M, Dean RA. Movement of small RNAs in and between plants and fungi. *Mol Plant Pathol*. 2020;21(4):589–601.
- Zhu C, Liu JH, Zhao JH, Liu T, Chen YY, Wang CH, et al. A fungal effector suppresses the nuclear export of AGO1-miRNA complex to promote infection in plants. *Proc Natl Acad Sci U S A*. 2022;119(12):e2114583119.
- Chang Z, Yadav V, Lee SC, Heitman J. Epigenetic mechanisms of drug resistance in fungi. *Fungal Genet Biol*. 2019;132:103253. doi:10.1016/j.fgb.2019.103253.
- O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. *Nat Rev Immunol*. 2010;10(2):111–22.
- Raisch J, Darfeuille-Michaud A, Nguyen HT. Role of microRNAs in the immune system, inflammation and cancer. *World J Gastroenterol*. 2013;19(20):2985.
- Kumar M, Topno RK, Kumar H, Kumar J. Biological conversion of Carcinogenic Aflatoxin B1 to AFB1-8, 9-exo-epoxide and its potential prevention. *Int J Res Anal Rev*. 2018;5(4):935–46.
- Chandan K, Gupta M, Sarwat M. Role of host and pathogen-derived microRNAs in immune regulation during infectious and inflammatory diseases. *Front Immunol*. 2020;10:3081.
- Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. *Indian J Med Res*. 2014;139(2):195–204.
- Ruhnke M, Behre G, Buchheidt D, Christopheit M, Hamprecht A, Heinz W, et al. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). *Mycoses*. 2018;61(11):796–813.
- Kumar M, Sahoo G, Topno R, Pandey K, Ravidas V, Dikhit M. Molecular interaction of antifungal compounds with fungal type I Polyketide synthase and preventing hepatocarcinogenesis. *Int J Infect Dis*. 2018;73:285.
- Shrivastava M, Pandey D, Sharma P, Singh R. MicroRNA regulation and host interaction in response to *Aspergillus* exposure. *Biocell*. 2022;46(2):339.
- Gupta MD, Fliesser M, Springer J, Breitschopf T, Schlossnagel H, Schmitt AL, et al. *Aspergillus fumigatus* induces microRNA-132 in human monocytes and dendritic cells. *Int J Med Microbiol*.

- 2014;304(5-6):592–6.
33. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Oncol.* 2015;26(1):21–33.
 34. Kumar M, Kumar H, Topno RK, Kumar J. Analysis of impact of anaerobic condition on the aflatoxin production in *Aspergillus parasiticus* Speare. *Ag Sci Dig Res J.* 2019;39(1):75–8.
 35. Marini TJ, Castaneda B, Iyer R, Baran TM, Nemer O, Dozier AM, et al. Breast ultrasound volume sweep imaging: a new horizon in expanding imaging access for breast cancer detection. *J Ultrasound Med.* 2023;42(4):817–32.
 36. Kumar M, Rana S, Kumar H, Kumar J, Mansuri R, Sahoo GC. Inhibition of product template (PT) domain of aflatoxin producing polyketide synthase enzyme of *Aspergillus parasiticus*. *Lett Drug Des Discov.* 2017;14(7):811–8.
 37. Chen F, Xu XY, Zhang M, Chen C, Shao HT, Shi Y. Deep sequencing profiles microRNAs related to *Aspergillus fumigatus* infection in lung tissues of mice. *J Microbiol Immunol Infect.* 2019;52(1):90–9.
 38. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole resistance in *Aspergillus* species: an emerging problem. *Drugs.* 2017;77(6):599–613.
 39. Mishra J, Kumar M, Sharan AK, Kumar J. Detoxification assessment of Aflatoxin in *Aspergillus flavus* under the effect of *Calendula officinalis* Linn's methanolic extract. *Ag Sci Dig Res J.* 2019;39(1):21–5.
 40. Kumar M, Akhtar MS. Application of Microbial Biotechnology in Improving Salt Stress and Crop Productivity. In: Kumar M, editor. *Salt Stress, Microbes, and Plant Interactions: Mechanisms and Molecular Approaches.* Singapore: Springer; 2019. p. 133–59. doi:10.1007/978-981-13-8805-7_7.
 41. Croston TL, Lemons AR, Beezhold DH, Green BJ. MicroRNA regulation of host immune responses following fungal exposure. *Front Immunol.* 2018;9:170.
 42. Shang J, Sun S, Zhang L, Hao F, Zhang D. miR-211 alleviates ischaemia/reperfusion-induced kidney injury by targeting TGF β R2/TGF- β /SMAD3 pathway. *Bioengineered.* 2020;11(1):547–57.
 43. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Front Endocrinol (Lausanne).* 2018;9:402. doi:10.3389/fendo.2018.00402.
 44. Ismail SM, Boghdady NAE, Hamoud H, Shabayek MI. Evaluation of circulating miRNA-208a-3p, miRNA-155-5p and miRNA-637 as potential non-invasive biomarkers and the possible mechanistic insights into pre- and postmenopausal osteoporotic females. *Arch Biochem Biophys.* 2020;684:108331. doi:10.1016/j.abb.2020.108331.
 45. Zeng L, Sun Y, Li X, Wang J, Yan L. 10-Hydroxycamptothecin induces apoptosis in human fibroblasts by regulating miRNA-23b-3p expression. *Mol Med Rep.* 2019;19(4):2680–6.
 46. Hegde M, Kumar A, Girisa S, Alqahtani MS, Abbas M, Goel A, et al. Exosomal noncoding RNA-mediated spatiotemporal regulation of lipid metabolism: Implications in immune evasion and chronic inflammation. *Cytokine Growth Factor Rev.* 2023;73:114–34.
 47. Banerjee S, Thompson WE, Chowdhury I. Emerging roles of microRNAs in the regulation of Toll-like receptor (TLR)-signaling. *Front Biosci (Landmark Ed).* 2020;26(4):771–96.
 48. Shin H, Jeon J, Lee JH, Jin S, Ha UH. *Pseudomonas aeruginosa* GroEL stimulates production of PTX3 by activating the NF- κ B pathway and simultaneously downregulating microRNA-9. *Infect Immun.* 2017;85(3):e00935–16.
 49. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. *Cell stem cell.* 2013;13(1):87–101.
 50. Bruch A, Kelani AA, Blango MG. RNA-based therapeutics to treat human fungal infections. *Trends Microbiol.* 2022;30(5):411–20.

Author biography

Maneesh Kumar, PhD Scholar  <https://orcid.org/0000-0002-0231-7162>

Roshan Kamal Topno, PG Student  <https://orcid.org/0000-0003-1412-7566>

Ratnesh Kumar, Assistant Professor  <https://orcid.org/0009-0001-9806-0364>

Cite this article: Kumar M, Topno RK, Kumar R. RNAi: antifungal therapy against Invasive pulmonary aspergillosis (IPA) in humans. *Indian J Microbiol Res* 2023;10(3):123-128.